The optimal treatment of follicular lymphoma (FL) is not well established. There is no doubt that the clinical development of rituximab (R) has been a significant breakthrough in FL. However, its effect on overall survival (OS) in these patients is still open to debate.
We reviewed 1076 patients treated in our country diagnosed with FL. They were included in the Follicular Lymphoma Registry, a prospective registry within GOTEĹs (Spanish Lymphoma Study Group) database that includes all new lymphoma cases, regardless of their histological subtype, diagnosed in the hospitals within the Group between January 1st 1999, and January 1st 2009. Data were obtained from 16 sites. The median follow up was 54.9 months (0.13-663.12) for the entire series.
The addition of R to the chemotherapy regimen was significantly associated with a superior OS (p 60 years of age (p = 0.05); ECOG > 1 (p = 0.002); Stage III-IV (p = 0.004); more nodal and extranodal involvement (p = 0.003); > LDH (p = 0.007); and higher FLIPI (p = 0.02). Nevertheless, patients with a high-risk disease, according to the FLIPI benefited the most from the addition of R whereas statistical significance was not reached for patients with a low/intermediate FLIPI score.
In our experience, R is associated with better overall survival, especially in patients with high risk FLIPI.
Clinical trial identification
Legal entity responsible for the study
Hospital Universitario Puerta de Hierro
Spanish Lymphoma Oncology Group (GOTEL)
All authors have declared no conflicts of interest.